Feedback
Settings

Settings

Goto Application

3,393 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(QXDXBKZJFLRLCM-UAKXSSHOSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 340
1.WO/2024/197309PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS
WO - 26.09.2024
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/US2024/021351 Applicant MODERNATX, INC. Inventor SEEPERSAUD, Mohindra
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
2.WO/2024/194153RSV-F-ENCODING NUCLEIC ACIDS
WO - 26.09.2024
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/EP2024/056893 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor BARROWS, Nicholas John
The present disclosure provides inter alia, a recombinant ribonucleic acid (RNA) encoding a respiratory syncytial virus fusion (RSV-F) protein comprising an F2 and an F1 domain; wherein the RSV-F protein further comprises, relative to a wild-type RSV-F sequence, the substitution of a residue for a C residue in both of the F2 and F1 domains.
3.WO/2024/194756MODULATING THE INNATE IMMUNITY OF RNA
WO - 26.09.2024
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/IB2024/052474 Applicant PFIZER INC. Inventor ALLEN, Pirada Suphaphiphat
The present disclosure provides methods and compositions for modulating the innate immunity to exogenous ribonucleic acid (RNA) when administered to a subject in need thereof. More particularly, the disclosure provides compositions comprising RNA encoding at least one antigen or therapeutic protein, and at least one compound that modulates the innate immunity to such RNA when administered to a subject in need thereof. The disclosure further provides methods of using such compounds to modulate the innate immunity of such compositions.
4.WO/2024/197307PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS
WO - 26.09.2024
Int.Class A61K 47/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
 Appl.No PCT/US2024/021344 Applicant MODERNATX, INC. Inventor SEEPERSAUD, Mohindra
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
5.WO/2024/193965RSV-F-ENCODING NUCLEIC ACIDS
WO - 26.09.2024
Int.Class C12N 15/45
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
45Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
 Appl.No PCT/EP2024/055127 Applicant GLAXOSMITHKLINE BIOLOGICALS SA Inventor BIANCUCCI, Marco
The present disclosure provides inter alia, a recombinant nucleic acid encoding a respiratory syncytial virus fusion (RSV-F) protein comprising a cytoplasmic tail; wherein, relative to a cytoplasmic tail according to SEQ ID NO: 3 or 4, 2-20 residues are deleted from the cytoplasmic tail of the RSV-F protein.
6.WO/2024/197310PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS
WO - 26.09.2024
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/US2024/021352 Applicant MODERNATX, INC. Inventor SEEPERSAUD, Mohindra
Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.
7.WO/2024/196875COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT AND MANAGEMENT OF OBESITY ASSOCIATED METABOLIC DYSFUNCTION
WO - 26.09.2024
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
 Appl.No PCT/US2024/020417 Applicant THE CHILDREN'S HOSPITAL OF PHILADELPHIA Inventor HILL, David
Compositions and methods for the management and treatment of obesity related metabolic dysfunction disorders are disclosed.
8.WO/2024/194266DEVICE AND METHOD FOR PRODUCING NUCLEIC ACID MOLECULES
WO - 26.09.2024
Int.Class B01L 3/00
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
3Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
 Appl.No PCT/EP2024/057179 Applicant QUANTOOM BIOSCIENCES S.A. Inventor DE LAMOTTE, Anne
A method for processing a liquid sample comprising one or more biochemical products, wherein said processing comprises: combining at least a fraction of said liquid sample with a plurality of magnetic particles to form a reactant mixture in a processing container, wherein the plurality of magnetic particles are able to bind to at least a portion of said biochemical products in the liquid sample; applying a magnetic source to the processing container, wherein biochemical products bound to the magnetic particles are separated from an unbound fraction of the liquid sample; removing at least a portion of said unbound fraction and retaining the plurality of magnetic particles bound to the biochemical products; and optionally washing the retained magnetic particles with a wash buffer wherein the processing container comprises at least an inner wall and an outer wall to form a processing space and wherein a distance between the inner wall and outer wall is less than 80 mm.
9.WO/2024/192257MRNA THERAPEUTICS FOR DISORDERS OF VASCULAR PERMEABILITY
WO - 19.09.2024
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No PCT/US2024/019965 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor PARHIZ, Hamideh
The present invention relates to compositions and methods for pulmonary targeted delivery of VE-cadherin and methods of use thereof for treating or preventing vascular permeability disorders, such as acute respiratory stress syndrome (ARDS).
10.WO/2024/192351TRANSIENT MODIFIED-RNA BASED ELEVATED EXPRESSION OF FLI-1 TO AUGMENT HEMATOPOIETIC STEM AND PROGENITOR CELL EXPANSION
WO - 19.09.2024
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/US2024/020161 Applicant CORNELL UNIVERSITY Inventor ITKIN, Tomer
The present disclosure is directed to a method of activation and expansion of adult non-activated hematopoietic stem and progenitor cells (HSPCs). The present disclosure reveals that Fli-1 activity is essential during regenerative hematopoiesis. Fli-1 directs activation programs while manipulating cellular sensory and output machineries, enabling HSPCs co-adoptability with a stimulated vascular niche. Applying FLI-1 transient modified-mRNA transduction into lethargic adult human mobilized HSPCs, enables their niche-mediated expansion and superior engraftment capacities. The present disclosure provides a population of regenerated and expanded adult hematopoietic stem and progenitor cells (HSPCs). The present disclosure also provides methods of treating a subject in need of activated and expanded adult HSPCs by administering the regenerated and expanded HSPCs to the subject.
# -